Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00795
|
|||||
| Drug Name |
Bicalutamide
|
|||||
| Synonyms |
(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Bicalutamide (JAN/USP/INN); Bicalutamide [USAN:INN:BAN]; Calutide (TN); Casodex; Casodex (TN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; Cosudex; Cosudex (TN); KS-1161; Kalumid (TN); N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; Propanamide; Raffolutil; Zeneca brand of bicalutamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Prostate cancer [ICD11: 2C82] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H14F4N2O4S
|
|||||
| Canonical SMILES |
CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
|||||
| InChI |
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
|
|||||
| InChIKey |
LKJPYSCBVHEWIU-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 90357-06-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 430.4 | Topological Polar Surface Area | 116 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
2.3
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:3090
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Bicalutamide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.